Successful mercaptopurine usage despite azathioprine-induced pancreatitis in paediatric Crohn's disease

Journal of Crohn's and Colitis

Volumn 9, Issue 8, 2015, Pages 676-679

  Gallego Gutiérrez, Silvia ^a   Navas López, Víctor Manuel ^a,b   Kolorz, Michal ^c,d   Bartosova, Ladislava ^c   Lukac, Katerina ^c   Luque Pérez, Silvia ^a   Núñez Caro, Leticia ^a   García Galán, Paloma ^a   Fernández Crehuet, Francisco Girón ^a   Blasco Alonso, Javier ^a,b   Serrano Nieto, María Juliana ^a   Sierra Salinas, Carlos ^a,b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b Institute of Biomedical Research of Malaga (IBIMA)   (Spain)

^c Faculty of Pharmacy   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Azathioprine; Children; Crohn's disease; Mercaptopurine; Pancreatitis; Thiopurines

Indexed keywords

AMYLASE; AZATHIOPRINE; AZITHROMYCIN; CORTICOSTEROID; MERCAPTOPURINE; METRONIDAZOLE; TRIACYLGLYCEROL LIPASE; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACUTE PANCREATITIS; ADOLESCENT; ARTICLE; CASE REPORT; CHILD; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERIC FEEDING; EPIGASTRIC PAIN; FEVER; GENE; GENETIC POLYMORPHISM; HUMAN; MALE; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; TPMT GENE; VOMITING; WILD TYPE; CHEMICALLY INDUCED; COMPLICATION; PANCREATITIS;

6-MERCAPTOPURINE; ADOLESCENT; AZATHIOPRINE; CHILD; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PANCREATITIS;

EID: 84973176480     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv086     Document Type: Article

References (29)

1. Ruemmele FM, Veres G, Kolho KL, et al. ECCO/ESPGHAN. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis 2014;8:1179-207
2. Gordon M, Taylor K, Akobeng AK, Thomas AG. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2014;8:CD010233
3. Stocco G, Martelossi S, Decorti G, Bartoli F, Ventura A. Thiopurine-Smethyltransferase genotype and the response to azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2007;26:1083-4;
4. Kennedy NA, Rhatigan E, Arnott ID, et al. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis. Aliment Pharmacol Ther 2013;38:1255-66
5. Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:973-83
6. Van Asseldonk DP, Sanderson J, De Boer N, et al. Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease proceedings of the first Thiopurine Task Force meeting. Dig Liver Dis 2011;43:270-6
7. Gisbert JP, Chaparro M, Gomollón F. Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol 2011;17:3467-78
8. Chaparro M, Ordás I, Cabré E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis 2013;19:1404-10
9. Stocco G, De Iudicibus S, Franca R, Addobbati R, Decorti G. Personalized therapies in pediatric inflammatory and autoimmune diseases. Curr Pharm Des 2012;18:5766-75
10. Beswick L, Friedman A, Sparrow M. The role of thiopurine metabolite monitoring in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2014;8:383-92
11. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 2005;20:1149-57
12. Gisbert JP, Gomollón F, Maté J, Pajares JM. Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyl transferase [TPMT] activity. Rev Clin Esp 2002;202:555-62
13. Shipkova M, Franz J, Abe M, Klett C, Wieland E, Andus T. Association between adverse effects under azathioprine therapy and inosine triphosphate pyrophosphatase activity in patients with chronic inflammatory bowel disease. Ther Drug Monit 2011;33:321-8
14. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14
15. Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002;111:360-7
16. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014;8:795-806
17. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011;17:1314-21
18. Turner D, Griffiths A, Walters TD, et al. Mathematical weighting of the pediatric Crohnś diasease activity index [PCDAI] and comparison with its other short versions. Inflamm Bowel Dis 2012;18:55-62
19. Beswick L, Hair CS, Dowling D. Successful mercaptopurine therapy after azathioprine-related pancreatitis in patients with IBD. Aliment Pharmacol Ther 2013;37:162
20. Ledder OD, Lemberg DA, Ooi CY, Day AS. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease? J Pediatr Gastroenterol Nutr 2013;57: 583-6
21. Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn's disease compared with other diseases. Aliment Pharmacol Ther 2004;20:843-50
22. Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprineinduced pancreatitis. Aliment Pharmacol Ther 2008;28:623-8
23. Van Geenen EJ, Deboer NH, Stassen P, et al. Azathioprine or mercaptopurine-induced acute pancreatitis is not a disease specific phenomenon. Aliment Pharmacol Ther 2010;31:1322-9
24. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurinemethyltransferase activity in inflammatory bowel disease patients maintained on lowdose azathioprine. Aliment Pharmacol Ther 2002;16:389-98
25. Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase [TPMT] activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 2006;53:399-404
26. Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, Van der Woude CJ. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2007;26:643-52
27. Wroblova K, Kolorz M, Batovsky M, et al. Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients. Dig Dis Sci 2012;57:2394-401
28. Stocco G, Pelin M, Franca R, et al. Pharmacogenetics of azathioprine in inflammatory bowel disease: a role for glutathione-S-transferase? World J Gastroenterol 2014; 20:3534-41
29. Heap GA, Weedon MN, Bewshea CM, et al. HLA-DQA1-HLA DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet 2014;46:1131-4